Celon Pharma SA (CLN) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Biogened SA

Celon Pharma SA

BIOTON SA

Ryvu Therapeutics SA

Captor Therapeutics SA

Synthaverse SA

Bioceltix SA

Molecure SA

E-shopping Group SA

Why is Celon Pharma SA ?

Poor Management Efficiency with a low ROE of 1.43%

The company has been able to generate a Return on Equity (avg) of 1.43% signifying low profitability per unit of shareholders funds

Poor long term growth as Operating profit has grown by an annual rate -230.19% of over the last 5 years

With a growth in Net Sales of 16.6%, the company declared Very Positive results in Mar 26

RAW MATERIAL COST(Y) Fallen by -60.87% (YoY)
NET SALES(Q) Highest at PLN 57.51 MM
PRE-TAX PROFIT(Q) Highest at PLN 162.35 MM

With ROE of 20.96%, it has a attractive valuation with a 2.02 Price to Book Value

Over the past year, while the stock has generated a return of -14.26%, its profits have risen by 1086.5% ; the PEG ratio of the company is 0

Below par performance in long term as well as near term

Along with generating -14.26% returns in the last 1 year, the stock has also underperformed Poland WIG in the last 3 years, 1 year and 3 months

Real-Time Research Report

Verdict Report

How much should you hold?

Overall Portfolio exposure to Celon Pharma SA should be less than 10%
Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock

Is Celon Pharma SA for you?

Low Risk, Medium Return

Absolute

Risk Adjusted

Volatility

Celon Pharma SA

-100.0%

1.12

24.69%

Poland WIG

29.57%

1.72

17.21%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

9.37%

EBIT Growth (5y)

-230.19%

EBIT to Interest (avg)

-10.38

Debt to EBITDA (avg)

Net Debt to Equity (avg)

-0.10

Sales to Capital Employed (avg)

0.49

Tax Ratio

23.15%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

ROCE (avg)

1.17%

ROE (avg)

1.43%

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

2.02

EV to EBIT

-22.36

EV to EBITDA

-255.10

EV to Capital Employed

2.00

EV to Sales

4.96

PEG Ratio

0.01

Dividend Yield

ROCE (Latest)

-8.94%

ROE (Latest)

20.96%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Bearish

RSI

No Signal

Bollinger Bands

Bearish

Moving Averages

Bearish (Daily)

KST

Bearish

Dow Theory

No Trend

Mildly Bullish

OBV

Mildly Bearish

Mildly Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

11What is working for the Company

RAW MATERIAL COST(Y)

Fallen by -60.87% (YoY

NET SALES(Q)

Highest at PLN 57.51 MM

PRE-TAX PROFIT(Q)

Highest at PLN 162.35 MM

NET PROFIT(Q)

Highest at PLN 162.6 MM

EPS(Q)

Highest at PLN 3.06

0What is not working for the Company

NO KEY NEGATIVE TRIGGERS

Here's what is working for Celon Pharma SA

Pre-Tax Profit

At PLN 162.35 MM has Grown at 977.7%

Year on Year (YoY)

MOJO Watch

Near term Pre-Tax Profit trend is very positive

Pre-Tax Profit (PLN MM)

Net Profit

At PLN 162.6 MM has Grown at 744.56%

Year on Year (YoY)

MOJO Watch

Near term Net Profit trend is very positive

Net Profit (PLN MM)

Net Sales

Highest at PLN 57.51 MM

in the last five periods

MOJO Watch

Near term sales trend is positive

Net Sales (PLN MM)

Pre-Tax Profit

Highest at PLN 162.35 MM

in the last five periods

MOJO Watch

Near term Pre-Tax Profit trend is positive

Pre-Tax Profit (PLN MM)

Net Profit

Highest at PLN 162.6 MM

in the last five periods

MOJO Watch

Near term Net Profit trend is positive

Net Profit (PLN MM)

EPS

Highest at PLN 3.06

in the last five periods

MOJO Watch

Increasing profitability; company has created higher earnings for shareholders

EPS (PLN)

Raw Material Cost

Fallen by -60.87% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales